Fate Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fate Therapeutics, Inc.
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics
As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.
As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Tfinity Therapeutics, Inc.